Breaking
RAPS Euro Convergence: Top Regulatory Insights - Day 1European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1
🇺🇸 FDA

Addiction Medicine

Page 1 • 1 item

Unlock insights into global addiction medicine markets. Stay ahead with pharma intelligence for BD, investment, and regulatory strategy.

Clearmind Medicine CMND-100 Meets Primary Safety Endpoint in Alcohol Use Disorder Trial
NewsAlcohol Use Disorder (AUD)Apr 21, 2026

Clearmind Medicine CMND-100 Meets Primary Safety Endpoint in Alcohol Use Disorder Trial

Clearmind Medicine announces positive safety results for CMND-100, its non-hallucinogenic psychedelic treatment for alcohol use disorder in Phase 1 trial.

Dr. Sarah Mitchell